Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 28 of 419 for:    TRANEXAMIC ACID

Tranexamic Acid Dosing for Total Joint Arthroplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02584725
Recruitment Status : Completed
First Posted : October 23, 2015
Last Update Posted : April 10, 2018
Sponsor:
Information provided by (Responsible Party):
Robert Maniker, Columbia University

Brief Summary:
The purpose of this study is to determine the effect of increasing doses of tranexamic acid (TXA) on limiting blood loss during total knee and total hip arthroplasty as defined by a change in hemoglobin from pre-operative baseline to the first post-operative day.

Condition or disease Intervention/treatment Phase
Arthropathy of Hip Arthropathy of Knee Drug: Tranexamic Acid Phase 4

Detailed Description:

The study is a prospective, randomized, double-blinded trial comparing three different doses of TXA (5mg/kg, 10mg/kg, 15mg/kg) in decreasing blood loss during and after total knee and total hip arthroplasty. Patients undergoing total knee arthroplasty and total hip arthroplasty will be analyzed separately, in sub-group analysis. The primary endpoint will be the change in hemoglobin from baseline to the first post-operative day (POD#1).

Patients will initially be identified by their orthopedic surgeon if they meet the inclusion and exclusion criteria. They will be informed about the study and provided with the consent form in the office, which they will be able to review further prior to the date of surgery. If the patient wishes to participate, formal written consent will be completed by one of the study investigators or a member of the regional anesthesia team. Patients will then be randomized to one of three groups. The anesthesia team responsible for the subject patient's care will receive two twenty milliliter syringes of medication. The syringe labeled "Study medication #1" will be administered intravenously over 20 minutes beginning at the start of surgical skin preparation, and the syringe labeled "Study medication #2" will be administered over 20 minutes beginning at the start of surgical wound closure. The syringes for group 1 (low-dose TXA) will each contain 5mg/kg TXA, diluted to 20 milliliters with saline. The syringes for group 2 (moderate-dose TXA) will each contain 10mg/kg TXA, diluted to 20 milliliters with saline. The syringes for group 3 (high-dose TXA) will each contain 15mg/kg TXA, diluted to 20 milliliters with saline. The anesthesia team will document the total intra-operative estimated blood loss as well as the amount of blood in the suction canister at the end of the surgery (as calculated by volume in the suction bucket minus volume of irrigation used).

The intraoperative course will be standardized for all patients included in the study. For total knee arthroplasty patients, the anesthesia will consist of a long-acting femoral or adductor canal peripheral nerve block, followed by a standardized spinal anesthetic using 15mg of plain isobaric bupivacaine. For total hip arthroplasty patients, the anesthesia will consist of a standardized spinal anesthetic using 15mg of plain isobaric bupivacaine. In those patients for whom spinal anesthesia is contraindicated or refused, general anesthesia will be performed and these patients will be excluded from the study. All patients initially enrolled, but excluded secondary to administration of a general anesthetic will be analyzed via an intention-to-treat method. Administration of intravenous crystalloid solutions will be per the discretion of the anesthesia team participating in the intra-operative portion of each patient's care, and will be documented for purposes of this study by the anesthesia team.

On PODs #0, #1 and #2, all patients will undergo standard post-operative blood work which includes a complete blood count. When working with physical therapy on POD#1 and POD#2, assessment of ability to sit, stand, and walk (yes/no) will be recorded. Assessment of pain scores via a VAS (0-10 scale, with 0 being no pain and 10 being the worst 05/26/2016 pain) will be recorded on POD#1 and POD#2. Assessment of subjective sense of overall wellbeing (a 0-10 scale, with 0 being the worst patients have ever felt, and 10 representing pre-operative baseline) will be recorded on POD #1 and #2. Patients will also be monitored via clinical exam for incidence of seizure, transient ischemic attack, stroke, myocardial infarction, deep venous thrombosis, and pulmonary embolus in the first 48 post-operatively.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Determining the Optimal Dose of Tranexamic Acid in Decreasing Blood Loss During Lower Extremity Total Joint Arthroplasty
Study Start Date : December 2014
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 5 mg/kg/dose tranexamic acid
5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
Drug: Tranexamic Acid
Comparison of 3 different doses of the drug
Other Name: Lysteda

Active Comparator: 10 mg/kg/dose tranexamic acid
10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
Drug: Tranexamic Acid
Comparison of 3 different doses of the drug
Other Name: Lysteda

Active Comparator: 15 mg/kg/dose tranexamic acid
15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
Drug: Tranexamic Acid
Comparison of 3 different doses of the drug
Other Name: Lysteda




Primary Outcome Measures :
  1. Change in hemoglobin from baseline to the first post-operative day (POD#1) [ Time Frame: 1 day ]

Secondary Outcome Measures :
  1. Change in hemoglobin from baseline to POD#0 [ Time Frame: 6 hours ]
  2. Change in hemoglobin from baseline to POD#2 [ Time Frame: 2 days ]
  3. Number of units of blood given from the intra-operative period into the end of POD#2 [ Time Frame: 2 days ]
  4. Total estimated intra-operative blood loss [ Time Frame: 2 hours ]
  5. Volume of blood in the surgical suction canister at the end of surgery [ Time Frame: 2 hours ]
  6. Mobility Assessment Score on POD1 and POD2 [ Time Frame: 2 days ]
    Unable to sit (score=0), able to sit (score=1), able to stand (score=2), and able to walk (score=3) during participation in physical therapy on POD#1 and POD#2

  7. Visual analog scale (VAS) pain scores on POD#1 and POD#2 [ Time Frame: 2 days ]
  8. Patients' self-reported scores on a scale of overall feeling of wellbeing on POD#1 and POD#2 [ Time Frame: 2 days ]
  9. Incidence of seizure, transient ischemic attack, stroke, myocardial infarction, deep venous thrombosis, and pulmonary embolus [ Time Frame: 2 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing primary unilateral total knee arthroplasty or primary unilateral total hip arthroplasty under spinal anesthesia at Columbia University Medical Center/ New York Presbyterian Hospital.

Exclusion Criteria:

  • Non-English speaking.
  • Patient refusal to participate.
  • Weight exceeding 100kg.
  • Baseline hemoglobin of less than 10.
  • Repeat, revision, or bilateral surgery.
  • Known sensitivity or allergy to Tranexamic Acid.
  • Active intra-vascular clotting.
  • History of coagulopathy or congenital thrombophilia.
  • Thromboembolic event in the 12 months prior to enrollment.
  • Percutaneous coronary intervention requiring a drug eluting stent in the 12 months prior to enrollment.
  • History of anticoagulant medication use unless stopped prior to surgery as recommended by and in accordance with the American Society of Regional Anesthesia Guidelines.
  • Use of a general anesthetic in the current anesthetic.
  • Blood transfusion for a hemoglobin value which deviates from the study's transfusion protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02584725


Sponsors and Collaborators
Columbia University
Investigators
Layout table for investigator information
Principal Investigator: Robert Maniker, MD Columbia University

Layout table for additonal information
Responsible Party: Robert Maniker, Assistant Professor of Anesthesiology, Columbia University
ClinicalTrials.gov Identifier: NCT02584725     History of Changes
Other Study ID Numbers: AAAM9601
First Posted: October 23, 2015    Key Record Dates
Last Update Posted: April 10, 2018
Last Verified: April 2018
Keywords provided by Robert Maniker, Columbia University:
Tranexamic Acid
Total Joint Arthroplasty
Intraoperative Blood Loss
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Hemostatics
Coagulants